Recent 8-K filings for CLSDQ

• Dec 29, 2025 23:59 UTC other_material materiality 0.95 negative item 1.03item 8.01item 9.01

  Clearside Biomedical bankruptcy court approves sale process; Health Ocean Limited as stalking horse

  Court approved bidding procedures on Dec 19, 2025; Health Ocean Limited designated as stalking horse bidder.

• Dec 08, 2025 23:59 UTC other_material materiality 0.85 negative item 3.01

  Clearside Biomedical files Form 25 to complete Nasdaq delisting after Chapter 11 bankruptcy

  Filed Form 25 on Dec 8, 2025 to delist from Nasdaq and deregister under Section 12(b); effective no earlier than Dec 18, 2025.

• Nov 25, 2025 23:59 UTC other_material materiality 0.90 negative item 1.03item 3.01item 7.01item 9.01

  Clearside Biomedical files for Chapter 11 bankruptcy; Nasdaq delisting effective Dec 1

  Filed voluntary Chapter 11 petition on Nov 23, 2025 in Delaware (Case No. 25-12109).

• Oct 07, 2025 23:59 UTC other_material materiality 0.50 positive item 8.01

  Clearside Biomedical regains Nasdaq minimum bid price compliance via reverse split

  Received Nasdaq Panel letter on Oct 6, 2025 confirming compliance with Minimum Bid Price Requirement.

• Sep 11, 2025 23:59 UTC other_material materiality 0.65 neutral item 5.03item 9.01

  Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M

  Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.

• Sep 11, 2025 23:59 UTC other_material materiality 0.65 neutral item 5.03item 9.01

  Clearside Biomedical files 1-for-15 reverse stock split, reduces authorized shares to 26.7M

  Reverse stock split effective September 12, 2025 at 5:00 p.m. ET; split-adjusted trading begins September 15, 2025.

• Sep 08, 2025 23:59 UTC other_material materiality 0.60 positive item 1.01

  Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap

  Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.

• Sep 03, 2025 23:59 UTC regulatory materiality 0.75 negative item 3.01item 5.07

  Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split

  Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.

• Aug 14, 2025 23:59 UTC regulatory materiality 0.80 negative item 3.01item 5.02

  Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds

  Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.

• Jul 17, 2025 23:59 UTC other_material materiality 0.85 negative item 2.05item 5.02item 8.01item 9.01

  Clearside explores strategic alternatives; all employees terminated, R&D paused

  All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.

• May 30, 2025 23:59 UTC other_material materiality 0.60 neutral item 5.03item 5.07item 9.01

  Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares

  Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.

• May 14, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02item 9.01

  Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD

  Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.

• Mar 27, 2025 23:59 UTC earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD

  Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event other_material

2 positive 6 negative 5 neutral

source · CLSDQ on sec.gov